Metrics to compare | 314130 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship314130PeersSector | |
|---|---|---|---|---|
P/E Ratio | −39.8x | −11.5x | −0.5x | |
PEG Ratio | −0.58 | −0.06 | 0.00 | |
Price/Book | 2.5x | 3.0x | 2.6x | |
Price / LTM Sales | 10.4x | 11.7x | 3.3x | |
Upside (Analyst Target) | - | 54.1% | 47.7% | |
Fair Value Upside | Unlock | 11.8% | 6.6% | Unlock |
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements. In addition, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD), as well as disorders related to gut-injury, including Necrotizing Enterocolitis (NEC). The company was founded in 2015 and is headquartered in Suwon-si, South Korea.